Acute Renal Failure Therapeutics Market to Expand Through 2033, Driven by Rising Acute Kidney Injury Cases and Advances in Treatment Research

The global acute renal failure therapeutics market was valued at USD 6.60 billion in 2025 and is projected to reach USD 13.05 billion by 2033, growing at a CAGR of 8.9% during the forecast period from 2026 to 2033.

The market is gaining momentum as healthcare providers focus on early diagnosis, timely intervention, and improved management of acute kidney injury (AKI). Increasing cases of kidney injury associated with critical illness, sepsis, cardiovascular complications, and hospital admissions are strengthening demand for effective therapeutic interventions. Advances in renal replacement therapy, continuous renal replacement therapy (CRRT), and investigational drug development are also creating opportunities to improve patient management and support the evolution of acute renal failure treatment.

Download Free Sample PDF Brochure: https://www.datamintelligence.com/download-sample/acute-renal-failure-therapeutics-market?sai-v

Recent Developments

October 24, 2026: AstraZeneca presented its SERENIA Phase 2a study of AZD4144 for sepsis-associated acute kidney injury at the American Society of Nephrology's Kidney Week 2026, highlighting ongoing research into potential therapeutic approaches for patients with kidney injury associated with sepsis.

October 21, 2026: Keenova Therapeutics announced two presentations examining TERLIVAZ (terlipressin) in hepatorenal syndrome-associated acute kidney injury, including real-world treatment outcomes and an analysis of renal replacement therapy.

October 14, 2026: A clinical trial published in the New England Journal of Medicine reported findings comparing intermittent hemodialysis with continuous renal replacement therapy in critically ill patients with acute kidney injury, adding evidence relevant to treatment selection and clinical outcomes.

September 4, 2026: The University of California, San Francisco, opened recruitment for the APRES-AKI study, investigating the feasibility and tolerability of restarting renin-angiotensin system inhibitor medications following acute kidney injury.

Key Players

Fresenius Medical Care, B. Braun Melsungen AG, Pfizer Inc., Medtronic, Baxter International Inc., Teleflex Incorporated, Cook Medical, Upsher-Smith Laboratories, LLC, Dialife SA, and Asahi Kasei Medical Co., Ltd.

Buy Now: https://www.datamintelligence.com/buy-now-page?report=acute-renal-failure-therapeutics-market?sai-v

Market Drivers

- Increasing prevalence of acute kidney injury among hospitalized and critically ill patients.

- Growing demand for renal replacement therapy and continuous renal replacement therapy.

- Rising investment in pharmaceutical research and development for kidney injury treatment.

- Increasing awareness of early diagnosis and timely intervention to reduce complications.

- Advancements in clinical research targeting inflammation, kidney tissue damage, and renal recovery.

Industry Developments

The acute renal failure therapeutics industry is advancing through research into drug candidates, improvements in renal replacement therapy, and clinical investigations focused on reducing kidney damage. Research is examining treatment approaches for sepsis-associated acute kidney injury, hepatorenal syndrome-associated kidney injury, and other complications affecting critically ill patients.

Recent clinical findings are also strengthening the focus on treatment selection and patient outcomes. Research published in October 2026 comparing intermittent hemodialysis with continuous renal replacement therapy highlights the importance of evaluating treatment strategies in critically ill populations. Meanwhile, ongoing investigations into therapeutic candidates and post-injury medication management are expanding the evidence base for acute kidney injury care.

Market Opportunities

The acute renal failure therapeutics market is projected to increase from USD 6.60 billion in 2025 to approximately USD 13.05 billion by 2033, representing an increase of approximately USD 6.45 billion over the forecast period. This growth outlook creates opportunities for pharmaceutical companies, biotechnology developers, dialysis equipment manufacturers, and renal care providers.

Potential opportunities include the development of targeted therapies, improved renal replacement technologies, and treatment approaches designed for patients with sepsis-associated kidney injury. Growing demand for intensive care services and improved kidney function monitoring may also support investment in advanced dialysis solutions and clinical diagnostic tools. Companies that demonstrate meaningful clinical benefits, safety, and practical integration into hospital workflows may be better positioned to address evolving treatment requirements.

Speak to our analyst and get customization in the report as per your requirements: https://www.datamintelligence.com/customize/acute-renal-failure-therapeutics-market?sai-v

Key Segments

By Disease Indication: Pre-renal Kidney Failure, Post-renal Kidney Failure, and Intrinsic Kidney Failure.

By Treatment: Medications/Drug Therapy, Dialysis, and Others.

By End User: Hospitals, Clinics, and Others.

Contact Us -

Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -

DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.